Insider Selling: Denali Therapeutics (NASDAQ:DNLI) Insider Sells $64,881.92 in Stock

Key Points

• Denali Therapeutics insider Alexander Schuth sold 2,768 shares for $64,881.92 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 0.98% to 278,995 shares.
• DNLI shares traded at $22.80, with a market capitalization of approximately $3.64 billion; the stock’s 12-month range is $12.58 to $27.30.
• Analysts maintain a “Moderate Buy” consensus, with an average price target of $35.85, while Denali’s latest quarterly loss of $0.68 per share missed estimates despite revenue exceeding forecasts.

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Alexander Schuth sold 2,768 shares of Denali Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the transaction, the insider owned 278,995 shares in the company, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics Price Performance

Denali Therapeutics stock traded down $0.05 during midday trading on Thursday, hitting $22.80. The company's stock had a trading volume of 1,727,974 shares, compared to its average volume of 1,712,119. The company has a market capitalization of $3.64 billion, a PE ratio of -8.03 and a beta of 1.01. Denali Therapeutics Inc. has a 12 month low of $12.58 and a 12 month high of $27.30. The stock's 50-day moving average price is $24.54 and its 200-day moving average price is $21.80. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period in the previous year, the business earned ($0.72) EPS. Analysts anticipate that Denali Therapeutics Inc. will post -2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DNLI shares. Sanford C. Bernstein reiterated a "hold" rating on shares of Denali Therapeutics in a report on Monday, June 22nd. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They set an "overweight" rating and a $29.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research report on Monday, July 13th. Morgan Stanley upped their target price on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Finally, Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a research note on Friday, August 7th. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Denali Therapeutics has an average rating of "Moderate Buy" and an average price target of $35.85.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its stake in Denali Therapeutics by 21.7% in the first quarter. Bank of America Corp DE now owns 1,134,183 shares of the company's stock valued at $21,776,000 after purchasing an additional 202,039 shares in the last quarter. Great Lakes Advisors LLC bought a new stake in shares of Denali Therapeutics in the second quarter valued at about $3,731,000. E. Ohman J or Asset Management AB acquired a new position in Denali Therapeutics during the 2nd quarter worth approximately $4,115,000. Sei Investments Co. bought a new position in Denali Therapeutics in the first quarter valued at $1,003,000. Finally, UBS Group AG boosted its position in Denali Therapeutics by 19.5% during the fourth quarter. UBS Group AG now owns 2,404,704 shares of the company's stock valued at $39,702,000 after purchasing an additional 392,351 shares during the last quarter. Institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source